fusidic acid has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blaschitz, K; Cespugli, M; Durmaz, V; Groiss, S; Gruber, CC; Gruber, K; Hetmann, M; Köchl, K; Krassnigg, A; Langner, C; Loibner, M; Ruau, D; Steinkellner, G; Zatloukal, K | 1 |
1 other study(ies) available for fusidic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification and validation of fusidic acid and flufenamic acid as inhibitors of SARS-CoV-2 replication using DrugSolver CavitomiX.
Topics: Acetylcholinesterase; COVID-19; Flufenamic Acid; Fusidic Acid; Humans; Papain; Peptide Hydrolases; SARS-CoV-2 | 2023 |